Associate Director R&D Business Development, Pfizer
Olivier has been with Pfizer for 20+ years. He joined the company in Sandwich, UK, initially as an organic chemist, before joining the Pfizer Business Development group focusing mainly on pre-clinical research collaborations and support of the Pfizer R&D organisation. He has supported a number of research groups in Pfizer, including gene therapy, Pfizer Centre for Therapeutic Innovation (CTI), and many other research units worldwide. Currently, he is the global Business Development lead for Drug Safety and Pharmaceutical Sciences Small Molecule groups.
In his Business Development role, he has managed many UK collaborations and public-private partnerships, including a number of open innovation research consortia funded by UKRI, and also Innovative Medicine Initiative (IMI) projects and has currently specific interest in continuous manufacturing and digitalisation of R&D processes. He also represents Pfizer on the Academic Collaboration, Education & Skills (ACES) ABPI group. Olivier is a passionate advocate of collaborative projects, and the power of bringing researchers from academia and industry together, ultimately for the benefit of the patient.